Publications


Publications
Probing Teichoic Acid Genetics with Bioactive Molecules Reveals New Interactions among Diverse Processes in Bacterial Cell Wall Biogenesis

Chemistry and Biology

D'Elia MA, Millar KE, Bhavsar AP, Tomljenovic AM, Hutter B, Schaab C, Moreno-Hagelsieb G, Brown ED
Chemistry and Biology - vol. 16 548-556 (2009)

The bacterial cell wall has been a celebrated target for antibiotics and holds real promise for the discovery of new antibacterial chemical matter. In addition to peptidoglycan, the walls of Gram-positive bacteria contain large amounts of the polymer teichoic acid, covalently attached to peptidoglycan. Recently, wall teichoic acid was shown to be essential to the […]

Publications
Automated high-content screening for compounds that disassemble the perinucleolar compartment.

Journal of biomolecular screening

Norton JT, Titus SA, Dexter D, Austin CP, Zheng W, Huang S
Journal of biomolecular screening - vol. 14 1045-1053 (2009)

All solid malignancies share characteristic traits, including unlimited cellular proliferation, evasion of immune regulation, and the propensity to metastasize. The authors have previously described that a subnuclear structure, the perinucleolar compartment (PNC), is associated with the metastatic phenotype in solid tumor cancer cells. The percentage of cancer cells that contain PNCs (PNC prevalence) is indicative […]

Publications
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders

Trends in Pharmacological Sciences

Conn PJ, Jones CK, Lindsley CW
Trends in Pharmacological Sciences - vol. 30 148-155 (2009)

Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer’s disease (AD) and other disorders involving impaired cognitive function. More recent evidence indicates that mAChR activators might also have utility in treating psychosis and other symptoms associated with schizophrenia and other central nervous system (CNS) […]

Publications
Hit finding: towards ‘smarter’ approaches

Current Opinion in Pharmacology

Langer T, Hoffmann R, Bryant S, Lesur B
Current Opinion in Pharmacology - vol. 9 589-593 (2009)

Drug discovery is complex and risky, and the chances of success are low. One starting point to discover a new drug is the selective screening of a collection of high value and good quality compounds. Selection of compounds for screening is one of the challenging initial steps in the drug discovery process and is crucial […]

Publications
High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv

Tuberculosis

Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, Maddry JA, Mehta A, Rasmussen L, Reynolds RC, Secrist JA, Shindo N, Showe DN, Sosa MI, Suling WJ, White EL
Tuberculosis - vol. 89 334-353 (2009)

There is an urgent need for the discovery and development of new antitubercular agents that target new biochemical pathways and treat drug resistant forms of the disease. One approach to addressing this need is through high-throughput screening of medicinally relevant libraries against the whole bacterium in order to discover a variety of new, active scaffolds […]

Publications
Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity

Journal of Biological Chemistry

Journal of Biological Chemistry - vol. 284 9394-9401 (2009)

Calcineurin phosphatase plays a crucial role in T cell activation. Dephosphorylation of the nuclear factors of activated T cells (NFATs) by calcineurin is essential for activating cytokine gene expression and, consequently, the immune response. Current immunosuppressive protocols are based mainly on calcineurin inhibitors, cyclosporine A and FK506. Unfortunately, these drugs are associated with severe side […]

Publications
A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution

Journal of Medicinal Chemistry

Auld DS, Zhang YQ, Southall NT, Rai G, Landsman M, MacLure J, Langevin D, Thomas CJ, Austin CP, Inglese J
Journal of Medicinal Chemistry - vol. 52 1450-1458 (2009)

We measured the « druggability » of the ATP-dependent luciferase derived from the firefly Photuris pennsylvanica that was optimized using directed evolution (Ultra-Glo, Promega). Quantitative high-throughput screening (qHTS) was used to determine IC(50)s of 198899 samples against a formulation of Ultra-Glo luciferase (Kinase-Glo). We found that only 0.1% of the Kinase-Glo inhibitors showed an IC(50) < 10 […]

Publications
Monitoring Compound Integrity with cytochrome P450 assays and qHTS

Www.Sbsonline.Org

MacArthur R, Leister W, Veith H, Shinn P, Southall N, Austin CP, Inglese J, Auld DS
Www.Sbsonline.Org 1-9 (2009)

The authors describe how room temperature storage of a 1120-member compound library prepard in either DMSO or in a hydrated-DMSO/water (67/33) mixture affects the reproducibility of potency values as monitored using cytochrome P450 1A2 and 2D6 isozyme assays. The bioluminescent assays showed Z’factors of 0.71 and 0.62, with 17% and 32% of the library found […]

Publications
A small molecule that directs differentiation of human ESCs into the pancreatic lineage.

Nature chemical biology

Chen S, Borowiak M, Fox JL, Maehr R, Osafune K, Davidow L, Lam K, Peng LF, Schreiber SL, Rubin LL, Melton D
Nature chemical biology - vol. 5 258-265 (2009)

Stepwise differentiation from embryonic stem cells (ESCs) to functional insulin-secreting beta cells will identify key steps in beta-cell development and may yet prove useful for transplantation therapy for diabetics. An essential step in this schema is the generation of pancreatic progenitors–cells that express Pdx1 and produce all the cell types of the pancreas. High-content chemical […]

Publications
Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization.

The Biochemical journal

Iorns E, Lord CJ, Ashworth A
The Biochemical journal - vol. 417 361-370 (2009)

Tamoxifen is the most commonly used drug to treat breast cancer and acts by blocking ERalpha (oestrogen receptor alpha) signalling. Although highly effective, its usefulness is limited by the development of resistance. Given this, strategies that limit resistance by sensitizing cells to tamoxifen may be of use in the clinic. To gain insight into how […]